All News

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.

Higher dietary fiber intake was associated with a reduced risk of moderate to severe diarrhea up to 2 years after diagnosis.

Combining 3 standard therapies into a single pill improved outcomes for adults with heart failure with reduced ejection fraction.

New research suggests stress cardiac MRI could help diagnose angina and improve quality of life for patients whose arteries appear clear on angiography.

RSV vaccines protected older adults against RSV-related hospitalization over 2 seasons, although with less effectiveness for those with immunocompromise or cardiovascular disease.

Eosinophilia serves as a significant biomarker for predicting immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors.

Only 4% of NIH prevention projects target health disparities, revealing a major gap between equity research and real-world implementation.

In a phase 3 trial, the investigational oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by nearly 60% in adults with or at risk for ASCVD.

Experts at AHA 2025 outlined how digital tools, inclusive trials, and safer deprescribing can reshape cardiovascular care for aging adults.

Brensocatib improves lung structure and reduces exacerbations in non-cystic fibrosis bronchiectasis with or without COPD, according to posters presented at this year's CHEST meeting.

The introduction of more stringent work requirements for those enrolling or renewing their Medicaid coverage can affect both children and adults.

Aligning patient and insurer incentives through price transparency, lower out-of-pocket costs, and broader networks could boost ASC use and access.

The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS, in relapsed/refractory LBCL.

Ritlecitinib significantly improves hair regrowth and reduces psychosocial burdens in patients with alopecia areata, enhancing emotional well-being over time.

Key factors influencing chronic urticaria duration highlight the importance of early identification and management in primary care settings.

As generative AI tools like ChatGPT, Gemini, and My AI gain popularity, new research highlights their growing role in youth mental health support.

Research shows how low-dose aspirin, lifestyle habits, and the Life’s Essential 8 checklist can affect cardiovascular risk in patients with type 2 diabetes.

Resmetirom showed comparable MASH resolution and fibrosis improvement in patients on GLP-1 RA or SGLT2i therapy and those on resmetirom alone.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Finerenone significantly reduced UACR in type 1 diabetes with chronic kidney disease, offering new hope for treatment.

CMS introduced the GENEROUS Model to reduce Medicaid drug costs, enhance access, and improve health outcomes for beneficiaries starting in 2026.

Combined or individual use of maternal RSVpreF and infant nirsevimab achieved high antibody levels without safety concerns, supporting current RSV prevention strategies.

The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), offering a new treatment for high-risk smoldering multiple myeloma.

Oncology experts at PCOC 2025 discuss breakthrough therapies, AI-driven care, and evolving care delivery models shaping the future of oncology.

Explore how the WISeR Model addresses prior authorization reform, Medicare costs, and AI's role in tackling the health care affordability crisis.

The White House announced significant drug pricing cuts for GLP-1s for diabetes and obesity for Medicare and Medicaid beneficiaries and on TrumpRx.

The efficacy of immune checkpoint inhibitors was found in patients with both HIV and non–small cell lung cancer (NSCLC), though more inclusion of people with HIV is needed in future studies.

Remibrutinib shows promise in treating generalized myasthenia gravis, with ongoing trials assessing its efficacy and safety for patients.